Clinical trial
Carmustine in Treating Patients With Recurrent Malignant Glioma
NCT00004028 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00004028 |
|---|---|
| Title | Carmustine in Treating Patients With Recurrent Malignant Glioma |
| Official title | PHASE I, OPEN LABEL, MULTICENTER DOSE ESCALATION STUDY OF GLIADEL IN PATIENTS WITH RECURRENT MALIGNANT GLIOMA |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug, Procedure |
| Interventions | carmustine, conventional surgery |
| Start date | Sep 1, 1996 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 9, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: